The Company
Swiss Bioscience GmbH (SBS) was
established in 2014 in Switzerland and is specialized in producing pharmaceutical quality grade stems cells
under cGMP* conditions. The cells are isolated from human adipose tissue to produce stromal vascular
fraction (SVF) which is then purified and expanded to produce human adipose tissue derived stem cells
(hADSCs).
SBS pursues research and development in the domain of stem cells, create new cell therapy based modalities for human medical use. SBS’ research program is based on utilisation of the paracrine effect of stem cells and is aimed at developing therapeutics from extracellular vesicles extracted from stem cells.
hADSC and SVF may only be used as a transplant product within the framework of a valid marketing authorization or within the framework of controlled clinical studies.
SBS pursues research and development in the domain of stem cells, create new cell therapy based modalities for human medical use. SBS’ research program is based on utilisation of the paracrine effect of stem cells and is aimed at developing therapeutics from extracellular vesicles extracted from stem cells.
hADSC and SVF may only be used as a transplant product within the framework of a valid marketing authorization or within the framework of controlled clinical studies.
Swiss Bioscience Team
Specialist in Orthopaedics, Traumatology & Sports-Orthopaedic Medicine
Univ. Lecturer and Ass. Professor of Medicine (Austria)
Prof. Dr. Gobert Freiherr
Our Purpose
Our aim is to improve and extend lives of people by developing cellbased treatments for regenerative medicine application. We aim to decrease the load of age – related diseases and enabling a healthier world.
Our Vision
Our vision is to lead the development of stem cell-based treatments and application, especially the treatments of human ailments using hADSCs.